Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Gilead and AI-focused Genesis partner to develop small molecule therapies

The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

- PMLiVE

Merck and Daiichi Sankyo’s ADC candidate ifinatamab deruxtecan shows promise in SCLC

Approximately 70% of small cell lung cancer patients are diagnosed with extensive-stage disease

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

- PMLiVE

Supporting Mental Health on Suicide Prevention Day: Mednet’s Commitment to Changing the Narrative

As part of Suicide Prevention Day, we take a look at the different ways we can support our colleagues' mental health and wellbeing and change the narrative around suicide

Mednet

- PMLiVE

Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m

The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly

- PMLiVE

GSK shares positive phase 3 results for long-acting biologic in severe asthma

Depemokimab is designed to allow for six-month dosing intervals for patients with the lung condition

regeneron headquarters

Regeneron’s Libtayo shows durable survival benefits in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Avalere Health appoints Corrina Safeio as president, global marketing

Safeio will also serve as executive vice president, corporate communications, and on the leadership team

- PMLiVE

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.

Petauri Evidence

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links